For Regrowing Human Limbs, This Salamander Gene Could Hold the Key
Scientists identified SP6 and SP8 as conserved genes that drive limb regeneration in axolotls, zebrafish and mice, and demonstrated that a viral gene‑therapy delivering FGF8 can partially rescue digit regrowth in mice lacking these genes. The work, published in PNAS, combined CRISPR knock‑outs, cross‑species comparative genomics and enhancer‑directed viral delivery to prove a gene‑therapy proof‑of‑concept for limb regeneration. With over a million amputations worldwide each year, the findings open a new therapeutic avenue beyond prosthetics and stem‑cell scaffolds. The collaborative model highlights the power of integrating diverse animal models to uncover universal regenerative pathways.
FDA Signals Potential Expansion of Testosterone Therapy to Treat Low Libido in Idiopathic Hypogonadism
The FDA announced it will entertain supplemental new drug applications to add low libido in men with idiopathic hypogonadism as an approved indication for existing testosterone replacement therapy (TRT) products. The move follows a December 2025 expert panel review of...
Clinical Trial of a Prion Disease Drug Candidate Begins Enrolling Participants
Broad Institute and UMass Chan have launched the first human trial of a prion disease therapy, a divalent small interfering RNA designed to silence the prion protein gene. The phase 1 PRiSM study will enroll 15 symptomatic patients to assess...
FDA Scientists Working in Satellite Laboratories Across U.S. Help Prevent Harmful Drugs From Reaching Americans
The FDA’s National Forensic Chemistry Center runs satellite laboratories inside high‑volume international mail hubs in Chicago, New York, Los Angeles, Miami and Honolulu. These compact labs use spectroscopy and mass spectrometry to screen incoming packages for counterfeit, unsafe or novel drug compounds...
RSV Vaccines Work to Prevent Hospitalization
Recent clinical data show that newly approved respiratory syncytial virus (RSV) vaccines dramatically cut hospital admissions. In infants, the vaccine lowered hospitalization risk by roughly 70%, while older adults experienced a 50% reduction in severe cases. The FDA has accelerated...
Roche to Start Phase III Trial to Broaden Access to Elevidys in Duchenne Muscular Dystrophy
Roche announced a global, pivotal Phase III trial of Elevidys, its gene‑therapy for Duchenne muscular dystrophy, targeting roughly 100 early‑ambulatory boys. The 72‑week, placebo‑controlled study will assess change in time‑to‑rise‑from‑floor velocity as the primary efficacy endpoint. Results are intended to bolster...
Study Data Technical Conformance Guide - Technical Specifications Document
The FDA has issued the final Study Data Technical Conformance Guide (Docket FDA-2014-D-0092), outlining technical specifications for electronic study data submissions. The guidance clarifies the agency’s expectations but remains non‑binding, allowing sponsors to use alternative approaches that meet regulatory requirements....
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee...
The FDA announced a public meeting on June 23, 2026 to discuss financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA VII), Biosimilar User Fee Act (BsUFA III) and Generic Drug User Fee Act (GDUFA III). The session will present five‑year financial...
Batch of Anti-Anxiety Drug Xanax Recalled, F.D.A. Says
The FDA announced a recall of a single batch of Xanax XR, the extended‑release formulation of the popular anti‑anxiety medication. Viatris, the drug’s distributor, is pulling 51 bottles of 3 mg tablets because they may not dissolve properly, potentially altering drug...
Toward Equitable Access to Cell and Gene Therapies: Rethinking Co-Payments
Cell and gene therapies now command one‑time price tags exceeding $3 million, creating affordability challenges for the U.S. health‑care system. While patient cost sharing represents a tiny slice of total spending, deductibles and coinsurance can still impose thousands of dollars in...
FDA Webinar on the RCT-DUPLICATE Initiative: Emulating Randomized Clinical Trials with Non-Randomized Real-World Data Studies - 04/29/2026
On April 29, 2026 the FDA hosted a free public webinar to update stakeholders on the RCT‑DUPLICATE demonstration project. The initiative compares non‑randomized real‑world data (RWD) studies with randomized controlled trial (RCT) outcomes to assess causal validity. Findings show strong...
FDA Extends Review of Savara’s Molgramostim BLA for PAP
Savara’s inhaled GM‑CSF therapy, molgramostim, received a three‑month FDA review extension, moving the PDUFA target action date to November 22, 2026. The extension follows the agency’s classification of the company’s recent data submissions as a major amendment, but it did not signal...
Musterdepot – Zukunft: In Unsicheren Zeiten Auf Die Moderne Infektionsmedizin Setzen
Investors are shifting focus from over‑valued tech names to the neglected anti‑infective sector as 2026 sees a market rotation. High‑priced AI and cloud stocks can tumble on modest earnings misses, prompting fund managers to seek defensive biotech exposure. Modern infection...
Regulatory Actions for April 16, 2026
BioWorld’s April 16, 2026 regulatory snapshot lists a flurry of biopharma and med‑tech actions, ranging from new drug submissions to market approvals and designations. Companies such as Airs, Aligos, AOP, Arbutus, Cala, Dogwood, Immutep, Leadiant, Northstar, Opna, Reach Surgical, Waters and Xspray...
STAT+: Researchers Behind GLP-1 Obesity Drugs Advance New Approach: Drop GLP-1 as a Target
Researchers who helped create GLP‑1 obesity drugs such as Eli Lilly’s Zepbound are now testing a different strategy. A team led by Richard DiMarchi and Matthias Tschöp engineered a molecule that activates GIP and glucagon receptors, showing weight‑loss results in...
FDA Approves Fast-Acting Heart Drug for Children
Austrian firm AOP Health received FDA approval for its fast‑acting IV beta‑blocker landiolol, marketed as Rapiblyk, to treat supraventricular tachycardia in pediatric patients. The decision follows the LANDI‑PED study, which enrolled 60 children and demonstrated more than a 20% reduction...
Developers Back Alzheimer’s Drugs Despite Report Suggesting Lack of Efficacy
A new Cochrane review of 17 trials involving 20,342 patients concludes that anti‑amyloid drugs for Alzheimer’s disease deliver only trivial or no clinically meaningful cognitive benefit and may increase the risk of amyloid‑related imaging abnormalities (ARIA). Eli Lilly’s donanemab (Kisunla) and...
STAT+: Cochrane Review Reignites Alzheimer’s Amyloid Wars
The FDA announced it will convene an external advisory panel to revisit rules on compounded peptides, with meetings slated for July and a follow‑up before February 2027. A new Cochrane review has reignited controversy over amyloid‑targeting Alzheimer’s therapies, questioning their...
Tumour Cells Use a Genetic Trick to Become Drug-Resistant
Researchers have identified that many tumor cells evade traditional Mendelian inheritance, enabling them to acquire drug‑resistance traits far faster than previously understood. The genetic maneuver involves non‑standard chromosome segregation and gene amplification, which let cancer cells adapt to chemotherapy pressures....
Pendulum Expands Mayo Clinic Collaboration Into Women’s Health and Dermatology
Pendulum Therapeutics is deepening its partnership with Mayo Clinic to launch interventional microbiome trials in women’s health and dermatology. The new studies will examine bone health in breast‑cancer patients, menopause transition, and the gut‑skin axis, moving beyond associative research. Pendulum...
Now Published - OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding
The phase III OCEANIC‑STROKE trial showed that adding Bayer's factor XIa inhibitor asundexian to standard antiplatelet therapy reduced recurrent ischemic strokes from 8.4% to 6.2% over two years, without raising major bleeding risk. The study enrolled 12,237 patients with recent non‑cardioembolic stroke...
7 Things to Know About the Nonprescription Drug Product with an Additional Condition for Nonprescription Use Final Rule
The FDA’s Center for Drug Evaluation and Research issued a final rule establishing an “Additional Condition for Nonprescription Use” (ACNU) pathway for over‑the‑counter medicines. Under ACNU, a drug can be sold without a prescription but must include an extra consumer‑screening...
Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) Using International Council for Harmonisation (ICH) E2B(R3)...
The U.S. Food and Drug Administration held two public meetings on April 4 and November 7, 2023 to outline upgrades to electronic adverse event reporting using the ICH E2B(R3) standard. The sessions targeted both pre‑market and post‑market safety surveillance programs managed by CDER and...
Proteins.1 Launches with €4.7m to Make Protein Detection as Easy as PCR
Proteins.1, a Finnish spin‑off, announced a €4.7 million (~$5.1 million) pre‑seed round to commercialise a PCR‑style protein amplification platform. The enzyme‑free, solid‑state technology uses magnetic cycling and thin‑film transistors to read a single captured protein repeatedly, delivering up to 1,000× greater sensitivity...
STAT+: Pharmalittle: We’re Reading About a Review of Alzheimer’s Drugs, FDA Interest in Compounded Peptides, and More
A Senate‑Democrats report released ahead of a drug‑pricing hearing shows that companies which signed pricing deals with former President Trump have continued to raise drug prices, with new therapies averaging $353,000 a year and combined profits climbing to $177 billion in...
Wegovy HD Now Available on GoodRx for $399 Per Month Self-Pay
GoodRx has launched a self‑pay option for Novo Nordisk’s Wegovy HD, a 7.2 mg semaglutide injection, priced at $399 per month and scaling to $798 for two months and $1,197 for three months. The higher‑dose formulation serves as an FDA‑approved step‑up...
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China
Aligos Therapeutics signed an exclusive license with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B candidate pevifoscorvir sodium in Greater China. The agreement provides Aligos with a $25 million upfront payment and up to $420 million in milestone fees, plus...
New Lab-Grown Organoids Accurately Mimic Pediatric Brain Tumor Biology
Scientists at St. Jude Children’s Research Hospital have created patient‑derived tumor organoids and organoid xenografts that faithfully recapitulate the genetic, epigenetic and cellular landscape of pediatric brain tumors. The 3D models, validated with DNA methylation, bulk and single‑cell RNA sequencing, and...
Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most
Gilead's long‑acting HIV pre‑exposure prophylaxis, lenacapavir, demonstrated almost 100% efficacy in trials and requires only two injections per year. The company can produce up to 10 million doses by 2026 but has pledged just 3 million through the Global Fund and PEPFAR,...
Interna Therapeutics Collaborates with Daiichi Sankyo to Develop MNM-Based Targeted Delivery Technologies
Interna Therapeutics announced a research collaboration with Daiichi Sankyo’s Boston Research Institute to evaluate its MNM (Molecular Nanoparticle Matrix) technology as a delivery enhancer for targeted therapeutics. The partnership will integrate MNM molecules with Daiichi Sankyo’s targeting approaches, beginning with...
Lilly's Obesity Pill Heads for Diabetes Filing After Heart Risk Trial
Eli Lilly’s newly approved obesity medication, marketed as Foun…, demonstrated a 16% lower incidence of major cardiovascular events compared with a standard insulin regimen in a recent trial. The data, presented by Lilly, suggest the drug not only aids weight loss...
Phase III Study of Lilly’s Foundayo, Reaffirms Cardiovascular and Overall Safety Profile, Plus Improvements to Cardiometabolic Health
Eli Lilly announced that its oral GLP‑1 drug Foundayo (orforglipron) achieved the primary endpoint in the Phase 3 ACHIEVE‑4 trial, demonstrating non‑inferior major adverse cardiovascular event risk versus insulin glargine. The study, the largest of its kind with over 2,700 participants...
What Happens When You Stop Ozempic or Mounjaro? New Study Reveals Surprising Weight-Loss Results
A Cleveland Clinic analysis of nearly 8,000 Ohio and Florida adults who stopped GLP‑1 injectables—semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound)—found minimal weight regain. Patients treated for obesity lost an average of 8.4% of body weight and regained only 0.5% after one...
STAT+: Roche to Launch Another Elevidys Trial, with Eyes on European Approval
Roche announced a new Phase 3 trial of Elevidys, the gene‑therapy for Duchenne muscular dystrophy, targeting European approval after a negative EMA review last year. The study will enroll roughly 100 boys in the early stages of the disease and compare...
LEO Pharma Reports the US FDA’s sNDA Acceptance of Anzupgo for Use in Children with Chronic Hand Eczema
LEO Pharma announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application for Anzupgo (delgocitinib) cream targeting adolescents aged 12 to 17 with moderate‑to‑severe chronic hand eczema. The acceptance follows the Phase III DELTA TEEN trial, which...
Breakthrough Science, Unequal Survival
Recent breakthroughs such as routine stem‑cell transplants and CAR‑T therapy have transformed treatment for several blood cancers, delivering long‑term remission for patients once deemed incurable. Yet blood cancer remains the UK’s third‑largest cancer killer, with 310,000 people living with or...
MRNA Vaccines Activate Unconventional CD8+ T Cells
A recent study published in *Nature Immunology* shows that mRNA COVID‑19 vaccines trigger a previously underappreciated subset of CD8+ T cells with innate‑like characteristics. These unconventional cells, resembling mucosal‑associated invariant T (MAIT) and γδ T cells, expand rapidly after the...
Innovation for a New Era of Cancer Care
The UK’s National Cancer Plan, released earlier this year, prioritises expanding genomic testing, liquid biopsies, and a national inherited cancer registry to modernise cancer pathways. Johnson & Johnson argues that linking these precision diagnostics to innovative therapies is essential for...
Cells Have a Secret 'Courier System' That Could Open Hard-to-Reach Targets for RNA and Gene Therapies
University College Dublin researchers have identified a previously unknown cellular "courier system" in which nanoparticles acquire a protein‑RNA "condensate corona" that shuttles functional biomolecules between cells. The corona forms a stable droplet that protects its cargo, escapes degradation, and delivers...
Decoding HBx–Smc6 Interaction: Advancing HBV Inhibition
A study in Cell Research reveals how hepatitis B virus protein HBx binds the host Smc6 subunit, triggering ubiquitin‑mediated degradation that lifts restriction on cccDNA and sustains infection. Cryo‑EM resolved the interface at near‑atomic resolution, identifying a pocket on Smc6 and...
Nucleai and Sirona Dx to Provide New Proteomics Solution for Pharma Companies
Nucleai and Sirona Dx have formed a partnership to deliver an end‑to‑end spatial proteomics solution for pharmaceutical and biotech companies. The joint offering unifies assay design, high‑quality imaging, and AI‑driven analytics to turn complex tissue data into actionable biological insights....
Phantom Neuro Secures Approval for Muscle-Machine Interface Trial
Phantom Neuro has received regulatory clearance to launch its first‑in‑human trial of the Phantom X muscle‑machine interface in Melbourne, Australia. The early feasibility study, called CYBORG, will enroll up to ten unilateral below‑elbow amputees who will receive a single outpatient implant...
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
Boehringer Ingelheim and Zai Lab have launched a Phase Ib/II trial that pairs Boehringer’s DLL3‑directed T‑cell engager obrixtamig with Zai Lab’s DLL3‑targeting ADC zoci. The study will evaluate safety, tolerability and early efficacy in patients with extensive‑stage small‑cell lung cancer and other neuroendocrine...
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
German pharma giant Boehringer Ingelheim and China‑based Zai Lab announced a clinical collaboration to evaluate a dual DLL3‑targeting regimen in extensive‑stage small‑cell lung cancer and other neuroendocrine tumors. The Phase Ib/II study will combine Boehringer’s bispecific DLL3/CD3 T‑cell engager obrixtamig with...
Freya Biosciences Advances Microbial Treatment for IVF Implantation Failure
Freya Biosciences announced that its microbial immunotherapy designed to address IVF implantation failure has progressed to a Phase 2 mid‑stage trial after demonstrating safety and early efficacy in healthy volunteers. The therapy leverages modulation of the uterine microbiome to improve endometrial...
AOP Health Reports the US FDA Approval Rapiblyk (Landiolol) for Pediatric Patients with Supraventricular Tachycardia
The U.S. Food and Drug Administration has granted approval for Rapiblyk (landiolol) for pediatric patients from birth through 17 years old suffering from supraventricular tachycardia (SVT). The decision follows the LANDI‑PED trial, which enrolled 60 children and demonstrated a greater...
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
Chinese biopharma Mabwell announced that the National Medical Products Administration has accepted a supplemental biologics license application for MAIWEIJIAN, its denosumab biosimilar. The 120 mg injection, already approved in China for giant cell tumor of bone and in Pakistan, is now...
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
A new Cochrane Review of 17 clinical trials involving more than 20,000 participants found that anti‑amyloid drugs—including lecanemab and donanemab—produce only trivial cognitive benefits and modest functional gains over 18 months. The analysis also highlighted a higher incidence of brain...
The Hallmarks of Cancer: 25 Years Guiding Discovery and Therapy
Twenty‑five years after the original six Hallmarks of Cancer were proposed, Douglas Hanahan updates the framework to incorporate new hallmarks such as deregulated metabolism, immune evasion, and the tumor microenvironment. Advances in genomics, single‑cell and spatial profiling have deepened insight...
Quantum Computers Take on Health Care: Light-Sensitive Cancer Drugs Win US$2-Million Contest
A team comprising Algorithmiq, IBM, and the Cleveland Clinic secured the $2 million Quantum for Bio prize by demonstrating a hybrid quantum‑classical simulation of a light‑sensitive cancer drug. The approach models photon‑electron interactions on IBM’s Quantum System One, revealing how molecular...